| scholarly article | Q13442814 |
| P2093 | author name string | Cheryl Smith | |
| Jim Robinson | |||
| John Rotrosen | |||
| Don Alderson | |||
| Edmund J Bini | |||
| Lawrence S Brown | |||
| Steven Kritz | |||
| Donald Calsyn | |||
| Kathlene Tracy | |||
| Patrick McAuliffe | |||
| P2860 | cites work | Global epidemiology of hepatitis C virus infection | Q27860799 |
| A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults | Q28278176 | ||
| Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention | Q28286743 | ||
| Global epidemiology of hepatitis B virus | Q28298592 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| Drug abuse treatment as an HIV prevention strategy: a review | Q33856563 | ||
| Chronic hepatitis B. | Q34002160 | ||
| National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. | Q34156940 | ||
| Drug abuse treatment as AIDS prevention. | Q34196421 | ||
| Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. | Q34289192 | ||
| Guidelines for the control of hepatitis A virus infection | Q34455964 | ||
| HAV infection in chronic liver disease: a rationale for vaccination | Q35126718 | ||
| Global burden of disease (GBD) for hepatitis C. | Q35610002 | ||
| Viral hepatitis B. | Q35617319 | ||
| Prevention of hepatitis A with the hepatitis A vaccine | Q35641793 | ||
| Review article: hepatitis vaccination in patients with chronic liver disease | Q35714136 | ||
| The importance and benefits of hepatitis A prevention in chronic liver disease patients | Q35780216 | ||
| Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs | Q35836781 | ||
| Clinical practice: prevention of hepatitis B with the hepatitis B vaccine | Q35996408 | ||
| Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment | Q36071292 | ||
| Evaluating existing recommendations for hepatitis A and B vaccination | Q36306885 | ||
| Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination | Q36306890 | ||
| Public health perspective on vaccine-preventable hepatitis: integrating hepatitis A and B vaccines into public health settings | Q36306933 | ||
| Hepatitis vaccination among drug users | Q36377325 | ||
| A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China | Q36617021 | ||
| Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network | Q36874071 | ||
| Sharing of noninjection drug-use implements as a risk factor for hepatitis C. | Q39530666 | ||
| Hepatitis C among noninjecting drug users: a report | Q39530685 | ||
| Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. | Q40481076 | ||
| A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States | Q40523181 | ||
| Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy | Q42602410 | ||
| A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma | Q42986473 | ||
| An outbreak of hepatitis A amongst injecting drug users | Q43813090 | ||
| Hepatitis C virus infection among noninjecting drug users in New York City | Q44453945 | ||
| Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). | Q44689724 | ||
| An outbreak of hepatitis A virus infection with a high case-fatality rate among injecting drug users | Q45424083 | ||
| Fulminant hepatitis A in intravenous drug users with chronic liver disease. | Q45933396 | ||
| Role of drug-abuse treatment in limiting the spread of AIDS. | Q51774681 | ||
| Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. | Q54074176 | ||
| Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C | Q60364371 | ||
| Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs | Q64128351 | ||
| Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994 | Q64132287 | ||
| Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP) | Q73137744 | ||
| Viral hepatitis and liver transplantation | Q79932057 | ||
| P433 | issue | 4 | |
| P921 | main subject | Hepatitis B virus | Q6844 |
| Hepatitis C virus | Q708693 | ||
| substance abuse | Q3184856 | ||
| P304 | page(s) | 438-445 | |
| P577 | publication date | 2011-10-27 | |
| P1433 | published in | Journal of Substance Abuse Treatment | Q15762042 |
| P1476 | title | Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States | |
| P478 | volume | 42 |
| Q37241384 | A qualitative analysis of provider barriers and solutions to HIV testing for substance users in a small, largely rural southern state |
| Q91598906 | Accelerated Hepatitis A and B Immunization in a Substance Abuse Treatment Program |
| Q34735072 | Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs |
| Q87870147 | Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study |
| Q33858322 | Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target? |
| Q37358615 | Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care |
| Q36562909 | Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance |
| Q33853664 | Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. |
| Q86617180 | Missed opportunities for hepatitis C testing in opioid treatment programs |
| Q37463091 | The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care plan |
| Q37423218 | Willingness to Receive Treatment for Hepatitis C among Injecting Drug Users on Methadone Program: Implications for Education and Treatment |
Search more.